Uterine cancer

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase I: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I

3 trials
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended
  • BioNTech Cell & Gene Therapies GmbH Commercial
    CLDN6 CAR-T; CLDN6 CAR-T(A); CLDN6 RNA-LPX; RBP030.2
    2024-514962-38-00 3 countries 2020 n=206
    Recruiting
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase I 0
BioNTech Cell & Gene Therapies GmbH Commercial 1 Phase I 1
Immunocore Limited Commercial 1 Phase I 1
New trials by year
2020
1
2023
1
2024
1
← All indication landscapes